| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | VASADE BIOSCIENCES INC | 16 E 27TH ST | BARNEGAT LIGHT | NJ | 08006-1522 | OCEAN | USA | R41AG080990 | A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease | 000 | 1 | NIH | 2/4/2025 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $187,151 ) |
| | 2023 | 2023 | VASADE BIOSCIENCES INC | 16 E 27TH ST | BARNEGAT LIGHT | NJ | 08006 | OCEAN | USA | R41AG080990 | A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease | 000 | 1 | NIH | 11/8/2022 | $252,130 |
| | 2023 | 2020 | VASADE BIOSCIENCES INC | 16 E 27TH ST | BARNEGAT LIGHT | NJ | 08006-1522 | OCEAN | USA | R44HL142390 | Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction | 000 | 3 | NIH | 3/1/2023 | -$64,980 |
|
| Issue Date FY: 2020 ( Subtotal = $715,042 ) |
| | 2020 | 2020 | VASADE BIOSCIENCES INC. | 16 E 27TH ST | BARNEGAT LIGHT | NJ | 08006 | OCEAN | USA | R44HL142390 | Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction | 000 | 3 | NIH | 9/5/2020 | $715,042 |
| | 2020 | 2019 | VASADE BIOSCIENCES INC. | 16 E 27TH ST | BARNEGAT LIGHT | NJ | 08006 | OCEAN | USA | R44HL142390 | Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction | 002 | 2 | NIH | 9/16/2020 | $40,028 |
| | 2020 | 2018 | VASADE BIOSCIENCES INC. | 16 E 27TH ST | BARNEGAT LIGHT | NJ | 08006 | OCEAN | USA | R44HL142390 | Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction | 001 | 1 | NIH | 9/16/2020 | -$40,028 |
|
| Issue Date FY: 2019 ( Subtotal = $673,385 ) |
| | 2019 | 2019 | VASADE BIOSCIENCES INC. | 16 E 27TH ST | BARNEGAT LIGHT | NJ | 08006 | OCEAN | USA | R44HL142390 | Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction | 002 | 2 | NIH | 4/19/2019 | $673,385 |
| | 2019 | 2018 | VASADE BIOSCIENCES INC. | 16 E 27TH ST | BARNEGAT LIGHT | NJ | 08006 | OCEAN | USA | R44HL142390 | Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction | 001 | 1 | NIH | 11/27/2018 | $0 |
| | 2019 | 2018 | VASADE BIOSCIENCES INC. | 16 E 27TH ST | BARNEGAT LIGHT | NJ | 08006 | OCEAN | USA | R44HL142390 | Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction | 000 | 1 | NIH | 11/12/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $172,153 ) |
| | 2018 | 2018 | VASADE BIOSCIENCES INC. | 16 E 27TH ST | BARNEGAT LIGHT | NJ | 08006 | OCEAN | USA | R44HL142390 | Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction | 000 | 1 | NIH | 8/15/2018 | $172,153 |
|
| Issue Date FY: 2017 ( Subtotal = $0 ) |
| | 2017 | 2014 | VASADE BIOSCIENCES INC. | 16 E 27TH ST | BARNEGAT LIGHT | NJ | 08006 | OCEAN | USA | R44HL112512 | AC5 inhibitor for heart failure | 000 | 3 | NIH | 6/19/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $0 ) |
| | 2016 | 2014 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R44HL112512 | AC5 inhibitor for heart failure | 000 | 3 | NIH | 3/31/2016 | $0 |
|
| Issue Date FY: 2014 ( Subtotal = $856,579 ) |
| | 2014 | 2014 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R44HL112512 | AC5 inhibitor for heart failure | 000 | 3 | NIH | 3/26/2014 | $856,579 |
|
| Issue Date FY: 2013 ( Subtotal = $764,406 ) |
| | 2013 | 2013 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R44HL112512 | AC5 inhibitor for heart failure | 000 | 2 | NIH | 7/3/2013 | $764,406 |
| | 2013 | 2012 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R43HL116052 | ACUTE CORONARY SYNDROME ANIMAL MODEL | 000 | 1 | NIH | 8/28/2013 | $0 |
|
| Issue Date FY: 2012 ( Subtotal = $373,599 ) |
| | 2012 | 2012 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R43HL116052 | ACUTE CORONARY SYNDROME ANIMAL MODEL | 000 | 1 | NIH | 8/20/2012 | $153,134 |
| | 2012 | 2012 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R43HL116052 | ACUTE CORONARY SYNDROME ANIMAL MODEL | 001 | 1 | NIH | 9/14/2012 | $14,796 |
| | 2012 | 2012 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R44HL112512 | AC5 inhibitor for heart failure | 000 | 1 | NIH | 4/16/2012 | $188,659 |
| | 2012 | 2012 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R44HL112512 | AC5 inhibitor for heart failure | 001 | 1 | NIH | 4/20/2012 | -$188,659 |
| | 2012 | 2012 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R44HL112512 | AC5 inhibitor for heart failure | 001 | 1 | NIH | 4/20/2012 | $188,659 |
| | 2012 | 2012 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R44HL112512 | AC5 inhibitor for heart failure | 002 | 1 | NIH | 9/2/2012 | $17,010 |
|
| Issue Date FY: 2011 ( Subtotal = $556,030 ) |
| | 2011 | 2011 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R42HL079729 | PREVENTION OF CARDIAC CELL DEATH BY MST1 INHIBITOR | 000 | 3 | NIH | 6/22/2011 | $556,030 |
|
| Issue Date FY: 2010 ( Subtotal = $817,193 ) |
| | 2010 | 2010 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R42HL079729 | PREVENTION OF CARDIAC CELL DEATH BY MST1 INHIBITOR | 000 | 2 | NIH | 6/18/2010 | $551,157 |
| | 2010 | 2010 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R41DK083826 | AC5 INHIBITOR FOR OBESITY | 000 | 1 | NIH | 8/3/2010 | $133,845 |
| | 2010 | 2010 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R43HL103026 | ANTIMIR-199A FOR CARDIAC ISCHEMIA AND FAILURE | 000 | 1 | NIH | 8/12/2010 | $132,191 |
|
| Issue Date FY: 2009 ( Subtotal = $0 ) |
| | 2009 | 2008 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R42HL082043 | PRIMATE MODEL FOR PHARMACEUTICAL DEVELOPMENT | 000 | 3 | NIH | 4/27/2009 | $0 |
|
| Issue Date FY: 2008 ( Subtotal = $382,485 ) |
| | 2008 | 2008 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R42HL082043 | PRIMATE MODEL FOR PHARMACEUTICAL DEVELOPMENT | 000 | 3 | NIH | 5/30/2008 | $382,485 |
|
| Issue Date FY: 2007 ( Subtotal = $393,566 ) |
| | 2007 | 2007 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R42HL082043 | PRIMATE MODEL FOR PHARMACEUTICAL DEVELOPMENT | 000 | 2 | NIH | 5/31/2007 | $393,566 |
|
| Issue Date FY: 2006 ( Subtotal = $145,499 ) |
| | 2006 | 2006 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R41HL086040 | PREVENTION OF NEOINTIMAL THICKENING BY MST1 | 000 | 1 | NIH | 7/28/2006 | $145,499 |
|
| Issue Date FY: 2005 ( Subtotal = $268,027 ) |
| | 2005 | 2005 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R41HL079729 | PREVENTION OF CARDIAC CELL DEATH BY MST1 INHIBITOR | 000 | 1 | NIH | 2/21/2005 | $141,802 |
| | 2005 | 2005 | VASADE BIOSCIENCES INC | 15 WEST 72ND STREET | NEW YORK | NY | 10023 | NEW YORK | USA | R41HL082043 | PRIMATE MODEL FOR PHARMACEUTICAL DEVELOPMENT | 000 | 1 | NIH | 9/5/2005 | $126,225 |
|
|
